Comic-Con 2025 set to kick off in a year that some major superheroes are sitting out
Just don't expect major news about the future of Marvel's movie slate or what's next for the hit relaunch of DC's high-flying 'Superman' franchise. Both studios are sitting out Comic-Con 2025, as far as their film slates go.
An estimated 135,000 people will attend the convention, which will greet Lucas on Sunday for his first Comic-Con appearance. The 'Star Wars' creator will discuss his new Lucas Museum of Narrative Art that will open next year in Los Angeles.
Fans of the 'Alien' and 'Predator' franchises will have plenty to cheer. Elle Fanning, star of 'Predator: Badlands,' will discuss the film at Comic-Con's massive Hall H this week. FX will also bring the stars and creators of 'Alien: Earth,' a series that will unleash the Xenomorph species on Earth next month.
'Alien: Earth' will be one of the projects that brings a massive interactive experience to San Diego, with a replica of spacecraft from the series. The attraction will feature what's described as a terrifying mission at night.
Marvel may not be presenting new movies, but it will have a 'Fantastic Four: First Steps' attraction near the convention, a tie-in to Friday's release of the latest attempt to successfully launch its 'first family' in theaters.
Thousands of fans got a sneak peek at the convention's 460,000 square foot (42,700 square meter) exhibitor section, which features exclusive merchandise, comic book art and exhibits from brands like Star Wars, Lego, Nickelodeon, Paramount and more.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Cutting-edge Diagnostic Technologies Transforming $6.4 Billion Landscape
The U.S. Alzheimer's disease diagnostics market, valued at USD 3.53 billion in 2024, is projected to grow at a CAGR of 10.6% from 2025-2030. Growth is driven by rising Alzheimer's prevalence and advanced diagnostics like FDA-approved blood tests, improving early detection and care planning. U.S. Alzheimer's Disease Diagnostics Market Dublin, July 28, 2025 (GLOBE NEWSWIRE) -- The "U.S. Alzheimer's Disease Diagnostics Market Size, Share & Trends Analysis Report By Diagnostic Technique (Biomarkers, Imaging Techniques, Genetic Testing, Cognitive Assessment Tests), By Type, By End-use, And Segment Forecasts, 2025 - 2030" report has been added to U.S. Alzheimer's disease diagnostics market was valued at USD 3.53 billion in 2024 and is expected to grow at a CAGR of 10.6% from 2025 to 2030 This growth is driven by the rising prevalence of Alzheimer's disease and increasing emphasis on early and accurate diagnosis. According to the U.S. Centers for Disease Control and Prevention (CDC), approximately 6.7 million older adults in the U.S. were living with Alzheimer's disease in 2024, a number projected to nearly double by 2060. The growing prevalence of the disease prompted government and private healthcare bodies to invest heavily in advanced diagnostic technologies such as PET imaging, cerebrospinal fluid biomarkers, and blood-based diagnostics. The growth of the U.S. Alzheimer's disease diagnostics market is due to the recent regulatory approval of advanced, non-invasive diagnostic technologies. The U.S. FDA granted marketing clearance for the first in vitro diagnostic device that utilizes a blood test to support the diagnosis of Alzheimer's disease. The Lumipulse G pTau217/b-Amyloid 1-42 Plasma Ratio is specifically intended for the early detection of amyloid plaque accumulation, a hallmark of Alzheimer's pathology, in adult patients aged 55 years and older who are exhibiting clinical signs and symptoms consistent with cognitive development represents a major advancement in Alzheimer's diagnostics, significantly lowering access barriers by providing a cost-effective and minimally invasive alternative to PET scans and lumbar punctures, which often carry procedural risks. The FDA highlighted that this approval makes it easier and potentially more accessible for U.S. patients earlier in the disease. It underscores the test's value in facilitating timely intervention and clinical decision-making in the early stages of Alzheimer's disease increasing rate of dementia diagnosis among older adults is driving the growth of the U.S. Alzheimer's diagnostics market. According to the 2022 National Health Interview Survey by the CDC, approximately 4% of individuals aged 65 and older have been diagnosed with dementia, with this figure rising to 13% among those aged 85 and above. This growth is primarily attributed to longer life expectancy, enhanced awareness, and improved diagnostic practices across clinical settings. The rising need for scalable, accurate diagnostic solutions to support early detection, appropriate intervention, and optimized care planning. Why should you buy this report? Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments. Competitive Landscape: Explore the market presence of key players worldwide. Future Trends: Discover the pivotal trends and drivers shaping the future of the global market. Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions. Key Attributes: Report Attribute Details No. of Pages 80 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $3.53 Billion Forecasted Market Value (USD) by 2030 $6.43 Billion Compound Annual Growth Rate 10.6% Regions Covered United States Competitive Landscape GE HealthCare Siemens Healthineers AG Canon Medical Systems Corporation Cerveau Technologies, Inc. Neurovision Imaging, Inc. Thermo Fisher Scientific Inc. Bio-Rad Laboratories, Inc. Quanterix Corporation Alzheon Inc. NanoSomiX, Inc. DiamiR Biosciences Company Overview Financial Performance Diagnostic Technique Portfolio Recent Developments/ Strategic Initiatives U.S. Alzheimer's Disease Diagnostics Market Report SegmentationDiagnostic Technique Outlook (Revenue, USD Million, 2018 - 2030) Biomarkers CSF Biomarkers Blood-Based Biomarkers Imaging Diagnostic Techniques Genetic Testing Cognitive Assessment Tests Type Outlook (Revenue, USD Million, 2018 - 2030) Triage Diagnosis Screening End Use Outlook (Revenue, USD Million, 2018 - 2030) Hospitals Diagnostic Laboratories Academic & Research Institutes For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment U.S. Alzheimer's Disease Diagnostics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
28 minutes ago
- Yahoo
Vogue readers horrified by use of ‘disturbing' AI models in Guess advert
Vogue readers have been left disturbed by the use of an AI model in the prestigious fashion magazine's August issue. The double-page advert, which features a blonde model wearing two different outfits across separate pages, was taken out by the label Guess and 'produced' by AI marketing Seraphinne Vallora. In one photo, the model sits with a cup of coffee in a light blue floral playsuit. In another, the AI figure leans against a blue wall in a black and white chevron print dress, clutching a matching Guess bag. Readers were alerted to the fact the model was AI generated through a fine print label that reads: 'Seraphinne Vallora on AI'. Seraphinne Vallora is an agency that designs 'editorial level AI-driven marketing campaigns and cinematic videos'. Its work has also been featured in Harper's Bazaar and Elle. 'That's disturbing. This is the direction AI should not be going in... wow,' one person wrote in response to the images of the AI model on X/Twitter. 'Great. The new beauty standard will be, literally, unobtainable because it's not real,' another social media user remarked. Others were more optimistic about the use of AI: 'The future is here. Takes less time and much cheaper to make,' one supporter wrote. The Independent has contacted Vogue, Guess and Seraphinne Vallora for comment. Plus size model Felicity Hayward, who has been in the fashion industry for over a decade, told the BBC that using AI models in campaigns 'feels lazy and cheap'. Hayward said Vogue's decision to include the advert was 'very disheartening and quite scary', adding she worried the practice could undermine years of work towards more diversity in the fashion industry. The controversy comes after OpenAI and Vogue's publisher Condé Nast announced a multi-year partnership that allows content from the magazine to appear in ChatGPT search results. Condé Nast's CEO, Roger Lynch, said in an email reported by the New York Times that it was 'crucial' for the publisher to 'meet audiences where they are and embrace new technologies'.
Medscape
30 minutes ago
- Medscape
Alcohol-Related Liver Disease Increases Sharply
Significant liver fibrosis associated with heavy alcohol use rose more than twofold over roughly the past two decades in the US despite alcohol use rates holding steady, which might be explained by risk factors for alcohol-related liver injury in the population, researchers said. Those most likely to be heavy drinkers are women, adults aged 45 years or older, those living in poverty, and those with metabolic syndrome, the data showed. 'Alcohol-related liver disease is the main cause of liver-related death, and these results are a major wake-up call to the dangers of drinking,' lead investigator Brian Lee, MD, MAS, hepatologist and liver transplant specialist with Keck Medicine of University of Southern California, Los Angeles, said in a statement. The study was published online on July 23 in Clinical Gastroenterology and Hepatology . Call for Increased Awareness To gauge trends in advanced alcohol-related liver disease among heavy drinkers, Lee and colleagues mined data from the National Health and Nutrition Examination Survey (NHANES) spanning 1999-2020. The primary outcome was a high Fibrosis-4 (FIB-4) score (FIB-4 > 2.67 for those aged 65 years or younger and > 3.25 for those older than 65 years), which has previously been linked to a 25-fold higher risk for liver-related death. People with hepatitis B or C were excluded. Among 44,628 adults, 2474 were heavy drinkers — defined as at least 20 g/d for women and 30 g/d for men in the prior year. Among heavy drinkers, the prevalence of high FIB-4 — a marker of advanced liver scarring — increased more than twofold over time, from 1.8% in 1999-2004 to 4.3% in 2013-2020, vs an increase of 0.8%-1.4% among non-heavy drinkers. Notably, average alcohol intake stayed the same during the study period, the researchers said. Among heavy drinkers, the prevalence of metabolic syndrome rose from 26.4% in 1999-2004 to 37.6% in 2013-2020, the mean age increased, and a greater proportion was women or living in poverty — factors that can amplify susceptibility to alcohol's liver effects. Supplementary analyses restricting the cohort to adults aged 35-65 years or to pre-pandemic years (1999-2018) confirmed the same upward trends, with significant liver scarring tripling over 20 years. Limitations cited by the authors include the cross-sectional design of NHANES and reliance on self-reported alcohol intake, which can't capture fluctuations over time, and the use of FIB-4 as a surrogate for liver disease. Collectively, the data suggest that increasing morbidity and mortality due to alcohol-related liver disease 'may be related to a population more sensitized to the alcohol-related effects in the liver due to increased baseline risk factors,' the researchers wrote. The findings provide impetus for 'urgent awareness' of the contemporaneous risk for alcohol-related liver disease with heavy drinking and interventions to screen and treat risk factors, they added.
